NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Nektar Therapeutics NKTR
17 fiscal years on record · USD · FY2025 reported · SEC filings only
Growth
USD 55.2M
Revenue, FY2025 · full 17-year series below
Revenue $B
Net income $B
FY2025 · Revenue 0.1 · Net income -0.2
Compound annual growth
Revenue compounded at −18.4% a year over five years.
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
−297 cents
lost on every revenue dollar
Operating margin
Net margin
FY2025 · Operating -253.7% · Net -297.1%
ROE
FY2025 · ROE -217.9%
Each USD of equity lost 218 cents this year.
The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
row low → row highnegative
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 1.2 | 0.3 | 0.2 | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 |
| Operating income $B | −0.1 | −0.1 | −0.3 | −0.4 | −0.4 | −0.4 | −0.4 | 0.7 | −0.1 | −0.1 | −0.0 | −0.0 | −0.1 | −0.1 | −0.1 | −0.0 | −0.1 |
| EBITDA $B | · | −0.1 | −0.3 | −0.4 | −0.4 | −0.4 | −0.4 | 0.7 | −0.0 | −0.1 | −0.0 | −0.0 | −0.1 | −0.1 | · | · | · |
| Income tax $B | −0.0 | −0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 | 0.0 | 0.0 | 0.0 | 0.0 | −0.0 |
| Net income $B | −0.2 | −0.1 | −0.3 | −0.4 | −0.5 | −0.4 | −0.4 | 0.7 | −0.1 | −0.2 | −0.1 | −0.1 | −0.2 | −0.2 | −0.1 | −0.0 | −0.1 |
| Free cash flow $B | −0.2 | −0.2 | −0.2 | −0.3 | −0.4 | −0.3 | −0.4 | 0.7 | −0.1 | −0.1 | −0.1 | −0.2 | −0.0 | −0.1 | −0.1 | −0.1 | 0.0 |
| EPS, diluted $ | −9.73 | −8.68 | −1.45 | −1.97 | −2.86 | −2.49 | −2.52 | 3.78 | −0.62 | −1.10 | −0.61 | −0.42 | −1.40 | −1.50 | −1.19 | −0.40 | −1.11 |
| Dividend / sh $ | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| Payout % | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · |
| ROE % | −217.9 | −124.1 | −110.9 | −70.4 | −59.6 | −35.8 | −28.2 | 75.5 | −109.9 | −324.7 | −379.7 | · | · | −140.4 | −92.9 | −39.3 | −100.1 |
| Shares out B | 0.02 | 0.01 | 0.19 | 0.19 | 0.19 | 0.18 | 0.18 | 0.17 | 0.16 | 0.15 | 0.14 | 0.13 | 0.12 | 0.12 | 0.11 | 0.09 | · |
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
Provenance
Company facts, as filed
How we verify · 0 failures in 64 reconciliationsAUDITED
Reconciled in 17 of 19 fiscal years. 14 checks could not be computed.
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2009